Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of inhaled Aviptadil on CCL18 serum concentrations in pulmonary fibrosis
2006-002174-22Phase 2Active
- Sponsor
- mondoBIOTECH AG
- Start
- Aug 2006
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, single-arm trial of aviptadil in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF), sponsored by mondoBIOTECH AG. Primary endpoint: CCL18 plasma concentration change. Started Aug 2006; status: active.
02
Drugs
aviptadil
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on 2006-002174-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002174-22.